Skip to main content
hero background ribbon

Our Pipeline

We are developing single-course gene editing medicines to disrupt today’s standard of care for cardiovascular disease. 

 

See Our Pipeline
Verve Scientist Verve team meeting Test tubes

Our Therapeutic Vision

Verve is taking a stepwise approach to clinical development with our single-course gene editing programs.

Pipeline step 1
Pipeline step 2
Pipeline step 3
Pipeline step 1

Step 01

Our initial focus will be on adults with familial hypercholesterolemia (FH), a genetic disease that leads to lifelong severely elevated LDL-C that increases the risk of early-onset atherosclerotic cardiovascular disease (ASCVD). FH affects approximately 3 million people in the U.S. and European Union and 31 million people globally.

Pipeline step 2

Step 02

If successful in FH, we plan to expand to a broader population of patients with established ASCVD who have a high risk for future cardiovascular events such as heart attack and stroke.

Pipeline step 3

Step 03

Ultimately, we plan to further expand to all adults at risk for ASCVD due to high LDL-C levels in the general population as a preventative measure.

Our Pipeline

Verve is advancing a pipeline of single-course in vivo gene editing programs intended to safely inactivate genes in the liver that contribute to ASCVD risk. Our initial programs target the PCSK9, ANGPTL3 and LPA genes, which have been validated via human genetics and human pharmacology as targets for lowering blood lipid levels. We envision expanding beyond these programs to develop a suite of single-course gene editing medicines that could address additional independent causes of ASCVD in the future.

ProgramIndicationsTechnologyResearchInd-enablingClinical
PCSK9
(VERVE-102)
Indications
Heterozygous familial hypercholesterolemia (HeFH)
ASCVD
Technology
Base Editor
Development Status
IND-Enabling
ANGPTL3
(VERVE-201)
Indications
Homozygous familial hypercholesterolemia (HoFH)
Refractory hypercholesterolemia
Technology
Base Editor
Development Status
IND-Enabling
LPA
(VERVE-301)
Indications
ASCVD with High Lp(a)
Technology
Novel Editor
Development Status
Research
Undisclosed
Indications
Undisclosed ASCVD
Technology
Novel Editor
Development Status
Research
Undisclosed
Indications
Undisclosed liver disease
Technology
Novel Editor
Development Status
Research
PRESENTATIONS & PUBLICATIONS

Read more about our latest data.